Mylan (NSDQ:MYL) was hit with another class action lawsuit over the price of its EpiPen device yesterday. The lawsuit, which was filed in the Washington Western District Court, alleges that Mylan engaged in a scheme with pharmacy benefit managers to dominate the market and overcharge customers.
Although the Canonsburg, Penn.-based company has been hit with several lawsuits in the last year over the price of its emergency allergy treatment, this is the 1st to focus on the role of pharmacy benefit managers. The plaintiffs, 3 EpiPen purchasers, brought their claims under the Raketeer Influenced and Corrupt Organizations Act – a federal law that is traditionally used against organized crime.
Get the full story at our sister site, Drug Delivery Business News.
The post EpiPen purchasers level class action against Mylan over price hikes appeared first on MassDevice.